Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global Markets
The global aptamer market was valued at $40 million in 2011 and should reach nearly $99 million in 2012. Total market value is expected to reach nearly $3.7 billion in 2017 with a five-year compound annual growth rate (CAGR) of 106.3%.
- An overview of the specific applications for nucleic acid aptamers for therapeutic and diagnostic purposes, with a focus on applications judged to be commercially viable rather than enabling of basic research
- Analyses of global market trends, with data from 2011, estimates for 2012, and projections of compound annual growth rates (CAGRs) through 2017
- Identification of emerging technology growth opportunities in aptamer use as adjuvants for siRNA delivery, vaccines, and antisense technologies
- Examination of high growth and market potential segments of the industry, and new and established companies in the arena
- Comprehensive company profiles of major players in the industry.
The scope of this report covers all major known applications of aptamers in the biotechnology arena. Nevertheless, the study focuses on applications judged to be commercially viable rather than enabling of basic research.
Dr. George William (“Bill”) Jackson, Ph.D., serves as a Senior Scientist at BioTex, Inc. in Houston, Texas. Additionally, Dr. Jackson is founder and chief scientist of Base Pair Biotechnologies, Inc., a company specializing in aptamer discovery services. He is an active researcher in the molecular biology and diagnostics field with numerous federal grants in the area. Particularly, he has served as principal investigator (PI) on several projects utilizing aptamers for both sensing and bioremediation. Most recently, he serves as PI on a research grant from the National Institutes of Health to select “an aptamer to everything,” which was formally titled, “Platform for Massively Parallel Selection of Aptamer Ligands.” He has served on peer review panels at the National Institutes of Health and the Environmental Protection Agency on topics ranging from biodefense and medical diagnostics to water quality. Dr. Jackson has authored more than 30 peer-reviewed publications or conference proceedings and is the inventor on four issued and 13 pending patents.
Co-author, Dr. Ulrich Strych, Ph.D., is a Research Assistant Professor at the University of Houston. Dr. Strych is an experienced molecular biologist who has collaborated with Dr. Jackson for more than five years on various aptamer-related research projects. Dr. Strych has extensive modern molecular biology experience, methods development know-how in surface plasmon resonance (SPR) and other bioanalytical approaches, and hands-on experience with other methods of high-throughput combinatorial screening, such as phage display.
The global market for aptamers is poised for significant new market entrants in the near future. In 2009 this market was valued at $10 million. By 2014, this market is estimated to be worth $1.9 billion, a compound annual growth rate (CAGR) of nearly 68%.
Aptamer therapeutic markets were valued at $10 million in 2009 and should increase at a 55% compound annual growth rate (CAGR) to $1.2 billion in 2014.
Aptamer diagnostic markets were worth $26 million in 2010 and are expected to increase in value to $659 million in 2014, a compound annual growth rate (CAGR) of 124%.